Precision Biosciences (DTIL) Receivables (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Receivables of $4.0 million for Q1 2026, up 99900.0% year-over-year from N/an in Q1 2025, and up 99900.0% quarter-over-quarter from $4000.0 in Q3 2025.
Precision Biosciences (DTIL) Receivables (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Receivables for 9 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 99900.0% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 99900.0% YoY), while the FY2024 annual figure was $229000.0, down 74.58% from the prior year.
- Receivables improved to $4.0 million in Q1 2026 per DTIL's latest filing, from $4000.0 in the prior quarter.
- Across five years, Receivables topped out at $50.5 million in Q2 2022 and bottomed at $4000.0 in Q1 2025.
- Historically, Receivables has averaged $4.2 million across 5 years, with a median of $652000.0 in 2023.
- Annual changes were most pronounced in 2025 — Receivables tumbled 98.97% — and 2026, when it surged 99900.0%.
- Precision Biosciences' Receivables stood at $720000.0 in 2022, then increased by 25.14% to $901000.0 in 2023, then plunged by 74.58% to $229000.0 in 2024, then tumbled by 98.25% to $4000.0 in 2025, then soared by 99900.0% to $4.0 million in 2026.
- Business Quant data shows DTIL's Receivables at $4.0 million in Q1 2026, $4000.0 in Q3 2025, and $4000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | - |
| 10 | Precision Biosciences | 224.82 Mn | 137.27 Mn | - | 3.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00 Mn |
| Sep 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 229,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Mar 31, 2024 | 390,000.00 |
| Dec 31, 2023 | 901,000.00 |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 652,000.00 |
| Mar 31, 2023 | 694,000.00 |
| Dec 31, 2022 | 720,000.00 |
| Sep 30, 2022 | 715,000.00 |
| Jun 30, 2022 | 50.51 Mn |
| Mar 31, 2022 | 488,000.00 |
| Dec 31, 2021 | 488,000.00 |
| Sep 30, 2021 | 488,000.00 |
| Jun 30, 2021 | 488,000.00 |
| Mar 31, 2021 | 19.26 Mn |
| Dec 31, 2020 | 10.00 Mn |